Radu POPP, Cristina HOTOLEANU, Adrian TRIFA, Daniela FODOR

The importance of homozygous polymorphisms of methylenetetrahydrofolate reductase gene in romanian patients with idiopathic venous thromboembolism

Background: Methylenetetrahydrofolate reductase (MTHFR) polymorphisms have recently raised the interest as a possible thrombophilic factors. Aims: We aimed to assess the frequency of the methylenetetrahydrofolate reductase (MTHFR) C677T and A1298C polymorphisms in idiopathic venous thromboembolism (VTE) in a Romanian population and the associated risk of VTE. Study Design: We performed a case-control transversal study including 90 patients diagnosed with VTE and 75 sex- and age-matched controls. Methods: MTHFR C677T and A1298C polymorphisms were detected using PCR-RFLP method. Results: The homozygous MTHFR 677TT genotype, present in 18.8% of patients with VTE versus 6.6% of controls, was significantly associated with VTE (p= 0.021, OR= 3.26, 95%CI (1.141-9.313)). The heterozygous MTHFR A1298C genotype, presenting the highest prevalence in the VTE group (34.4%) as well as in controls (37.3%), was not associated with VTE (p=0.7). No associations were found for heterozygous MTHFR C677T (with a frequency of 32.2% in VTE and 37.3% in controls, p=0.492), respective homozygous MTHFR A1298C genotype (with a frequency of 1.1% in VTE and 2.6% in controls, p=0.456). Conclusion: Among MTHFR polymorphisms, only homozygosity for MTHFR 677TT may be considered a risk factor for VTE; the MTHFR A1298C polymorphism is not significantly associated with an increased risk of VTE.

PDF

___

1. Whire RH. The epidemiology of venous thromboembolism. Circulation 2003;107 Suppl 1:I4-8.
2. Anderson FA Jr, Spencer FA. Risk factors for venous thromboembolism. Circulation 2003;107 Suppl 1:I9-16. [CrossRef]
3. Lovricevic I, Franjic BD, Tomicic M, Vrkic N, De Syo D, Hudorovic N, et al. 5, 10-Methylenetetrahydrofolate reductase (MTHFR) 677 C --> T genetic polymorphism in 228 Croatian volunteers. Coll Antropol 2004;28:647-54.
4. Pepe G, Camacho Vanegas O, Giusti B, Brunelli T, Marcucci R, Attanasio M, et al. Heterogeneity in world distribution of the thermolabile C677T mutation in 5,10-Methylenetetrahydrofolate reductase. Am J Hum Genet 1998;63:917-20. [CrossRef]
5. Wilcken B, Bamforth F, Li Z, Zhu H, Ritvanen A, Redlund M, et al. Geographical and ethnic variation of the 677C>T allele of 5,10 methylenetetrahydrofolate reductase (MTHFR): findings from over 7000 newborns from 16 areas world wide. J Med Genet 2003;40:619-25. [CrossRef]
6. Mayor-Olea A, Callejón G, Palomares AR, Jiménez AJ, Gaitán MJ, Rodríguez A, et al. Human genetic selection on the MTHFR 677C>T polymorphism. BMC Med Genet 2008;9:104. [CrossRef]
7. Guéant-Rodriguez RM, Guéant JL, Debard R, Thirion S, Hong LX, Bronowicki JP, et al. Prevalence of methylenetetrahydrofolate reductase 677T and 1298C alleles and folate status: a comparative study in Mexican, West African, and European populations. Am J Clin Nutr 2006;83:701-7.
8. Castro R, Rivera I, Ravasco P, Jakobs C, Blom HJ, Camilo ME et al. 5,10-Methylenetetrahydrofolate reductase 677C-->T and 1298A- ->C mutations are genetic determinants of elevated homocysteine. QJM 2003;96:297-303 [CrossRef]
9. Chango A, Boisson F, Barbé F, Quilliot D, Droesch S, Pfister M, et al. The effect of 677C-->T and 1298A-->C mutations on plasma homocysteine and 5,10-methylenetetrahydrofolate reductase activity in healthy subjects. Br J Nutr 2000;83:593-6. [CrossRef]
10. Kupeli E, Verdi H, Simsek A, Atac FB, Eyuboglu FO. Genetic muta- tions in Turkish population with pulmonary embolism and deep venous thrombosis. Clin Appl Thromb Hemost 2011;17:E87-94. [CrossRef]
11. Moheimani F, Jackson DE. Venous thromboembolism: classification, risk factors, diagnosis, and management. ISRN Hematol 2011;2011:124610.
12. Almawi WY, Tamim H, Kreidy R, Timson G, Rahal E, Nabulsi M, et al. A case control study on the contribution of factor V-Leiden, prothrombin G20210A, and MTHFR C677T mutations to the genetic susceptibility of deep venous thrombosis. J Thromb Thrombolysis 2005;19:189-96. [CrossRef]
13. Nizankowska-Mogilnicka E, Adamek L, Grzanka P, Domagala TB, Sanak M, Krzanowski M, et al. Genetic polymorphisms associated with acute pulmonary embolism and deep venous thrombosis. Eur Respir J 2003;21:25-30. [CrossRef]
14. Jang MJ, Jeon YJ, Choi WI, Choi YS, Kim SY, Chong SY, et al. The 677C>T Mutation of the MTHFR Gene Increases the Risk of Venous Thromboembolism in Koreans and a Meta-Analysis From Asian Population. Clin Appl Thromb Hemost 2012 Feb 12. [Epub ahead of print].
15. Bezemer ID, Doggen CJ, Vos HL, Rosendaal FR. No association between the common MTHFR 677C->T polymorphism and venous thrombosis: results from the MEGA study. Arch Intern Med 2007;167:497-501. [CrossRef]
16. Naess IA, Christiansen SC, Romundstad PR, Cannegieter SC, Blom HJ, Rosendaal FR, et al. Prospective study of homocysteine and MTHFR 677TT genotype and risk for venous thrombosis in a general population--results from the HUNT 2 study. Br J Haematol 2008;141:529-35. [CrossRef]
17. Keijzer MB, Borm GF, Blom HJ, Bos GM, Rosendaal FR, den Hei- jer M. No interaction between factor V Leiden and hyperhomo- cysteinemia or MTHFR 677TT genotype in venous thrombosis. Results of a meta-analysis of published studies and a large case- only study. Thromb Haemost 2007;97:32-7.
18. Key NS, McGlennen RC. Hyperhomocyst(e)inemia and thrombo- philia. Arch Pathol Lab Med 2002;126:1367-75.
19. Grody WW, Griffin JH, Taylor AK, Korf BR, Heit JA; ACMG Factor V. Leiden Working Group. American College of Medical Genetics consensus statement on factor V Leiden mutation testing. Genet Med 2001;3:139-48. [CrossRef]
20. Baglin T, Gray E, Greaves M, Hunt BJ, Keeling D, Machin S, et al. Clinical guidelines for testing for heritable thrombophilia. Br J Haematol 2010;149:209-20. [CrossRef]
21. Cushman M. Inherited risk factors for venous thrombosis. Hema- tology Am Soc Hematol Educ Program 2005:452-7. [CrossRef]
22. Mansilha A, Araujo F, Severo M, Sampaio SM, Toledo T, Albuquerque R. Genetic polymorphisms and risk of recurrent deep venous thrombosis in young people: prospective cohort study. Eur J Vasc Endovasc Surg 2005;30:545-9. [CrossRef]
23. Alfirevic Z, Simundic AM, Nikolac N, Sobocan N, Alfirevic I, Ste- fanovic M, et al. Frequency of factor II G20210A, factor V Leiden, MTHFR C677T and PAI-1 5G/4G polymorphism in patients with venous thromboembolism: Croatian case control study. Biochemia Medica 2010;20:229-35. [CrossRef]
24. Avdonin PV, Kirienko AI, Kozhevnikova LM, Shostak NA, Baba- daeva NM, Leont’ev SG, et al. C677T mutation in methylenetet- rahydrofolate reductase gene in patients with venous thromboses from the central region of Russia correlates with a high risk of pulmonary artery thromboembolism. Ter Arkh 2006;78:70-6.
25. Spiroski I, Kedev S, Antov S, Arsov T, Krstevska M, Dzhekova- Stojkova S, et al. Association of methylenetetrahydrofolate reductase (MTHFR-677 and MTHFR-1298) genetic polymorphisms with occlusive artery disease and deep venous thrombosis in Macedonians. Croat Med J 2008;49:39-49. [CrossRef]
26. Tatarskyy P, Kucherenko A, Livshits L. Allelic polymorphism of F2, F5 and MTHFR genes in population of Ukraine. Tsitol Genet 2010;44:3-8.
27. Pernod G, Biron-Andreani C, Morange PE, Boehlen F, Constans J, Couturaud F, et al. Recommendations on testing for thrombo- philia in venous thromboembolic disease: A French consensus guideline. J Mal Vasc 2009;34:156-203. [CrossRef]
28. Baytan B, Meral AG, İlçöl YO, Günay U. The prevalence of factor V Leiden (1691G-A)and methylenetetrahydrofolate reductase C677T mutations in healthy newborns in Bursa, Turkey. Turk J Hematol 2007;24:90-2.
29. Margaglione M, D’Andrea G, d’Addedda M, Giuliani N, Cappucci G, Iannaccone L, et al. The methylenetetrahydrofolate reductase TT677 genotype is associated with venous thrombosis indepen- dently of the coexistence of the FV Leiden and the prothrombin A20210 mutation. Thromb Haemost 1998;79:907-11.
30. Koch HG, Nabel P, Junker R, Auberger K, Schobess R, Hom- berger A, et al. The 677T genotype of the common MTHFR thermolabile variant and fasting homocysteine in childhood venous thrombosis. Eur J Pediatr 1999;158 Suppl 3:S113-6. [CrossRef]
31. Dordević V, Rakićević L, Spasić M, Miković D, Kovać M, Radojković D. Factor V Leiden, FII G20210A, MTHFR C677T mutations as risk factors for venous thrombosis during pregnancy and puerperium. Vojnosanit Pregl 2005;62:201-5. [CrossRef]
32. Angelopoulou K, Nicolaides A, Constantinou Deltas C. Prevalence of genetic mutations that predispose to thrombophilia in a Greek Cypriot population. Clin Appl Thromb Hemost 2000;6: 104-7. [CrossRef]
33. Salomon O, Steinberg DM, Zivelin A, Gitel S, Dardik R, Rosenberg N, et al. Single and combined prothrombotic factors in patients with idiopathic venous thromboembolism: prevalence and risk assessment. Arterioscler Thromb Vasc Biol 1999;19:511-18. [CrossRef]
34. García-Hernández MC, Romero Casanova A, Marco Vera P. Clinical comments on genetic marker prevalence (factor V Leiden, prothrombin 20210A and homozygous methylenetetrahydrofo- late reductase form [Ho-MTHFR]): based on a study conducted in Health Department No. 19 of the Valencian Community. Rev Clin Esp 2007;207:26-8. [CrossRef]
35. Couturaud F, Oger E, Abalain JH, Chenu E, Guias B, Floch HH, et al. Methylenetetrahydrofolate reductase C677T genotype and venous thromboembolic disease. Respiration 2000;67:657-61 [CrossRef]
36. Ray JG, Shmorgun D, Chan WS. Common C677T polymorphism of the methylenetetrahydrofolate reductase gene and the risk of venous thromboembolism: meta-analysis of 31 studies. Pathophysiol Haemos Thromb 2002;32:51-8. [CrossRef]
37. Den Heijer M, Lewington S, Clarke R. Homocysteine, MTHFR and the risk of venous thrombosis: a meta-analysis of published epidemiological studies. J Thromb Haemost 2005;3:292-9. [CrossRef]
38. Obeidat NM, Awidi A, Sulaiman NA, Abu-Khader IB. Thrombophilia-related genetic variations in patients with pulmonary embolism in the main teaching hospital in Jordan. Saudi Med J 2009;30:921-5.
39. Tsai AW, Cushman M, Tsai MY, Heckbert SR, Rosamond WD, Aleksic N, et al. Serum homocysteine, thermolabile variant of methylene tetrahydrofolate reductase (MTHFR), and venous thromboembolism: Longitudinal Investigation of Thromboembolism Etiology (LITE). Am J Hematol 2003;72:192-200. [CrossRef]
40. Domagala TB, Adamek L, Nizankowska E, Sanak M, Szczeklik A. Mutations C677T and A1298C of the 5,10-methylenetetrahydro- folate reductase gene and fasting plasma homocysteine levels are not associated with the increased risk of venous thromboembolic disease. Blood Coagul Fibrinolysis 2002;13:423-31. [CrossRef]
41. Stamatian F, Caracostea G, Muresan D, Bartok I, Militaru M, Pro- copciuc L, et al. The evaluation of inherited thrombophilic condi- tions in patients with bleeding in the first trimester of pregnancy. HVM Bioflux 2009;1:1-7.
42. Popp R, Crisan T, Militaru M, Rotar IC, Farcas M, Pop IV. The C677T Variant in the Methylenetetrahydrofolate Reductase Gene and Idiopathic Spontaneous Abortion in a Romanian Population Group. Not Sci Biol 2012;4:7-11.
43. Hanta I, Soydas Y, Karatasli M, Koseoglu Z, Satar S, Hasturk S. Plasma homocysteine level and 677C-->T mutation on the MTH- FR gene in patients with venous thromboembolism. Bratisl Lek Listy 2010;111:70-3.
44. McCarthya C, Ryan F, Vaughan J. Increased frequency of the MTHFR A1298C mutation in an Irish population. Clinical Chemistry 2004;50:2462-3. [CrossRef]
45. Tug E, Aydin H, Kaplan E, Dogruer D. Frequency of genetic muta- tions associated with thromboembolism in the Western Black Sea Region. Intern Med 2011;50:17-21. [CrossRef]
46. Franco RF, Morelli V, Lourenço D, Maffei FH, Tavella MH, Piccina- to CE, et al. A second mutation in the methylenetetrahydrofolate reductase gene and the risk of venous thrombotic disease. Brit J Haematol 1999;105:556-9. [CrossRef]
47. González-Porras JR, García-Sanz R, Alberca I, López ML, Balan- zategui A, Gutierrez O, et al. Risk of recurrent venous thrombosis in patients with G20210A mutation in the prothrombin gene or factor V Leiden mutation. Blood Coagul Fibrinolysis 2006;17:23- 8. [CrossRef]
48. Mansilha A, Araújo F, Severo M, Sampaio SM, Toledo T, Albuquer que R. Genetic polymorphisms and risk of recurrent deep venous thrombosis in young people: prospective cohort study. Eur J Vasc Endovasc 2005;30:545-9. [CrossRef]
49. Baglin T, Luddington R, Brown K, Baglin C. Incidence of recurrent venous thromboembolism in relation to clinical and thrombophil- ic risk factors: prospective cohort study. Lancet 2003;362:523-6. [CrossRef]
50. Keijzer MB, den Heijer M, Blom HJ, Bos GM, Willems HP, Gerrits WB, et al. Interaction between hyperhomocysteinemia, mutat- ed methylenetetrahydrofolatereductase (MTHFR) and inherited thrombophilic factors in recurrent venous thrombosis. Thromb Haemost 2002;88:723-8.
51. Joffe HV, Goldhaber SZ. Laboratory thrombophilias and venous thromboembolism. Vascular Medicine 2002;7:93-102 [CrossRef]
52. Vayá A, Plumé G, Bonet E, Carrasco P, Morales-Suárez-Varela MM. Hyperhomocysteinemia and the methylene tetrahydrofo- late reductase C677T mutation in splanchnic vein thrombosis. Eur J Haematol 2011;86:167-72. [CrossRef]
53. Sottilotta G, Siboni SM, Latella C, Oriana V, Romeo E, Santoro R, et al. Hyperhomocysteinemia and C677T MTHFR genotype in patients with retinal vein thrombosis. Clin Appl Thromb Hemost 2010;16:549-53. [CrossRef]